Gregory Giugliano, MD
Interventional Cardiology · West Columbia, SCNPI 1730147661
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Boston Scientific at 57.6% of the total. Reporting peaked in 2024 at $7,990 and has fallen 89.2% since, to $861 in 2025.
Across 100 payments — averaging $245.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$14K
- Amgen$7K
- Stryker$557
- Edwards Lifesciences$502
- Terumo Medical Corporation$494
- Shockwave Medical, Inc$253
- plus $1K from 12 others
Across 53 payments — averaging $2210.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$53K
- Daiichi Sankyo Inc.$22K
- Biotronik Inc.$20K
- Abbott$19K
- Philips North America LLC$3K
What the payments were for
- Consulting fees$10,75044%
- Speaking & faculty fees$6,88428%
- Travel & lodging$2,71211%
- Food & beverage$4,18217%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $14,142 |
| Amgen | 9 | $7,305 |
| Stryker | 11 | $557 |
| Edwards Lifesciences | 13 | $502 |
| Terumo Medical Corporation | 2 | $494 |
| Shockwave Medical, Inc | 6 | $253 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $249 |
| Inari Medical, Inc. | 3 | $235 |
| Abbott | 2 | $224 |
| Medtronic | 4 | $159 |
| Pfizer | 5 | $98 |
| Abiomed | 1 | $71 |
| Novo Nordisk | 2 | $56 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Kestra Medical Technology Services, Inc. | 1 | $43 |
| AstraZeneca | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Novartis | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$7,134
- GENERAL VASCULAR ACCESS$5,190
- GENERAL - THERAPIES$4,591
- GENERAL - STRUCTURAL HEART$4,000
- FLOWTRIEVER CATHETER, S$221
- CT THROMBECTOMY SYSTEM KIT$221
- CLOTTRIEVER BOLD CATHETER$170
- Optitorque$144
- GlideWire$144
- ANGIO-SEAL$144
- AVVIGO Guidance System$142
- FlowTriever$140
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$138
- XIENCE SKYPOINT$117
- ONYX FRONTIER$107
- MitraClip$107
How this compares
$24,545 in reported general payments places this provider in the 80th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 28 | $23,935 |
| EliquisApixaban | 17 | $23,048 |
| BrilintaTicagrelor | 14 | $6,861 |
| Atorvastatin Calcium | 74 | $670 |
| Ezetimibe | 40 | $578 |
| Metoprolol Succinate | 34 | $470 |
| Rosuvastatin Calcium | 33 | $284 |
| Losartan Potassium | 16 | $246 |
| Amlodipine Besylate | 25 | $199 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 28 | $196 |
| ClopidogrelClopidogrel Bisulfate | 21 | $178 |
| Metoprolol Tartrate | 17 | $85 |
| Lisinopril | 12 | $69 |
| Spironolactone | 13 | $66 |
| Carvedilol | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $98 | $23,04817 claims |
| AstraZenecaBrilinta | $43 | $6,86114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in West Columbia
- Robert LeonardiWest Columbia$203K
- Christopher PerryWest Columbia$26K
- Robert MalanukWest Columbia$25K
- Garrett RuthWest Columbia$14K
- Jonathan HewettWest Columbia$11K
- Brandon DraftsWest Columbia$11K
- William BrearleyWest Columbia$10K
- Brian WallWest Columbia$10K
- Daniel SteinbergCharleston$611K
- Brian BrownSpartanburg$389K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.